EORTC: 60 YEARS OF PROGRESS IN CLINICAL CANCER RESEARCH
September 30th, 2022 marked the celebration of the 60th Anniversary of the founding of the European Organisation for Research and Treatment of Cancer (EORTC) at a thought-provoking conference. This event, held in Brussels, brought together EORTC members, partners, patient advocates and many other key stakeholders in cancer research.
Celebrating the past
In celebration of the EORTC’s achievements, a Gala Dinner was hosted by the EORTC and HRH Princess Dina Mired of Jordan, Honorary President of ECRF*-EORTC, in the presence of HSH Prince Albert II of Monaco (immediate past Honorary President of the ECRF). Over 200 guests joined the celebrations at the Gala dinner on Thursday evening and around 400 people attended the conference on Friday at the Square, Brussels to discuss the past and future of EORTC.
“Cancer kills more than 10 million people every year”; HRH Princess Dina Mired addressed the importance of cancer prevention and control in her welcome address, stating that: “People are what matter at the EORTC. This organisation has understood the need for cancer research to be inclusive of all patients and all types of cancer and has successfully managed to advance research aimed not only at increasing patients’ survival, but also at improving their quality of life”.
EORTC embraces all types of therapeutic options and strives to optimise this for each individual cancer patient. Today, EORTC is active in more than 45 countries and in over 750 cancer institutes and hospitals.
Advancing clinical cancer research
The 60th Anniversary conference provided the opportunity to hear from key experts on how clinical cancer research has evolved over the past 60 years, and what the future should look like for the EORTC. There were discussions with policymakers on how independent clinical research can help shape European policies for optimising access to cancer treatments.
“We are an organisation with breakthrough cancer research, but also with over 40 years’ history of research in the field of quality of life”, Winette van der Graaf, EORTC President, highlighted; adding: “We can embrace the opportunities that EORTC has to offer and build on its achievements to maintain therapeutic progress for all cancer patients”.
Inspiring the future of cancer treatment
“Looking ahead, and true to its mission to advance cancer research for all patients leaving no one behind, EORTC will strive to address an academic agenda of multidisciplinary, clinically relevant questions. The importance of such agenda in the process of treatment development and access has been a key take-home message from the meeting. Furthermore, EORTC is currently exploring how to expand in the Middle East”, Denis Lacombe, EORTC Chief Executive Officer, mentioned in his opening address, adding: “this will allow EORTC to bring what we can to patients in this part of the world as well”.
Collaboration, quality, innovation and ability to look ahead and plan for what is happening in the wider world, is what EORTC will continue to aim for in the decades to come.
To learn more about our work, check out EORTC’s cancer clinical research. For more information or questions email us at firstname.lastname@example.org.
You can also help support EORTC’s game-changing clinical research to unleash scientific breakthrough and transform cancer patients’ lives. Learn how to GET INVOLVED, or Make a Contribution Now.